Introduction
Rapid reperfusion by percutaneous coronary intervention (PCI) is the preferred treatment for ST-segment elevation myocardial infarction (STEMI). 1, 2 However, myocardial tissue hypoperfusion persists after primary PCI in a substantial portion of patients despite restored patency of the epicardial coronary circulation. The principal cause of this phenomenon, termed no-reflow, is severe microvascular dysfunction or loss of integrity leading to microvascular obstruction (MVO). [3] [4] [5] The pathophysiology of MVO is complex and includes mechanisms such as distal embolization of thrombus and/or plaque, humoral-mediated vasospasm, and direct ischaemia-related and/or reperfusion-associated injury. The reference standard to visualize and quantify MVO is cardiac magnetic resonance imaging (CMR), with MVO signified by the lack of gadolinium enhancement within the hyperenhanced infarcted area ( Figure 1) . 6, 7 In the absence of adequately powered studies, the correlation of MVO with clinical outcomes in STEMI has not been fully characterized. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] We therefore performed a pooled analysis using individual patient data (IPD) from seven randomized trials of primary PCI in STEMI to examine the relationship between MVO assessed within 7 days after reperfusion and subsequent all-cause mortality, hospitalization for heart failure (HF), and reinfarction within 1-year follow-up.
Methods
The present study represents a collaborative effort between the principal investigators of randomized trials that enrolled patients with STEMI undergoing primary PCI in whom MVO was assessed by CMR within 7 days after reperfusion at a core laboratory and in whom clinical followup was performed for at least 6 months (unless death occurred earlier), with adverse events adjudicated by an independent clinical events committee. Seven such studies were available and their IPD were entered into a common database at the Cardiovascular Research Foundation (New York, NY, USA), as previously described. 18 The objectives of the current analysis were to examine the relationship between MVO as assessed by late gadolinium enhancement imaging and clinical outcomes. The primary endpoint of interest was the combination of all-cause mortality or hospitalization for HF. Secondary endpoints included the individual components of the primary composite endpoint as well as reinfarction. Our hypothesis was that after adjustment for differences in baseline clinical and angiographic variables, MVO would be independently correlated with all-cause mortality and HF hospitalization, but not necessarily with reinfarction.
Studies and definitions
The seven primary PCI trials included in the pooled analysis were (in approximate chronological order of patient enrolment): the CMR substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial, in which patients undergoing primary PCI were randomized to intravenous pexelizumab vs. placebo; 19 (no acronym), in which patients with anterior STEMI undergoing primary PCI were randomized in a 2 Â 2 design to an intralesional bolus of abciximab vs. control, and to thrombus aspiration vs. control. 25 Patients were included in the database in whom MVO was measured by late gadolinium enhancement imaging within 7 days and analyzed by an independent core laboratory masked to randomization assignment and outcomes. The scan protocols and details on image analysis have previously been described. [19] [20] [21] [22] [23] [24] [25] In brief, all studies used standard inversion Figure 1 Example of microvascular obstruction and infarct size assessed by cardiac magnetic resonance imaging. The hypoenhanced area (orange) corresponds to microvascular obstruction within the hyperenhanced infarct (yellow). 24 No imputations were performed for patients dying before MVO assessment or in whom MVO was not measured. For studies in which multiple CMR scans were available, MVO assessed by the earliest CMR scan was used. Infarct size was also measured by CMR during the same study as previously described. 18 The definitions and adjudicated events from each study were used in the present analysis.
Statistical analyses
The impact of MVO on death, HF hospitalization, and reinfarction as well as the combination of death or HF hospitalization from the time of study entry to latest follow-up was assessed using Cox proportional hazards regression. The following variables, which were common in all the datasets, were entered into the proportional hazards regression models: age, gender, diabetes, hypertension, hyperlipidaemia, current smoking, left anterior descending (LAD) vs. non-LAD infarct vessel, symptom-to-first device time, baseline thrombolysis in myocardial infarction (TIMI) flow 0/ 1 vs. 2/3, and MVO. To account for potential heterogeneity across studies, the standard errors in the regression equations were adjusted by including a random effect for study. Finally, as we have previously reported that infarct size is a powerful determinant of death or HF after primary PCI, 18 we included infarct size in additional models to determine if MVO remained an independent predictor of outcomes after controlling for this variable. The degree of multicollinearity of MVO with the entire covariate set, including infarct size, was estimated using the variance inflation factor. This was calculated as 1 -(1 -r 2 ), where r 2 was obtained from the multivariable linear regression of MVO on the entire covariate set.
In each model, the proportional hazards assumption was tested by evaluating the interaction term of each covariate by time. If the regression coefficient for any of these interaction terms was significant, the corresponding survival functions were graphed and as long as these functions did not cross the variable was included in the model. Using these criteria, the proportional hazards assumption was found to be tenable for all covariates.
The net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated to assess the added predictive value of MVO. 18 The standard model for these analyses included age, gender, diabetes, hypertension, hyperlipidaemia, current smoking, LAD vs. non-LAD infarct vessel, symptom-to-first device time, and baseline TIMI flow 0/1 vs. 2/3. The full model included these same nine variables plus MVO. Net reclassification improvement indicates the extent to which subjects are more appropriately classified as being high risk vs. low risk in multivariable models with vs. without the new variable. Integrated discrimination improvement indicates the extent to which the new variable differentiates individuals along a continuum of predicted risk. If the addition of MVO leads to prediction of higher probabilities of events for subjects that have events and lower probabilities of events for subjects that do not, NRI and IDI will be positive and significant. If the addition of MVO leads to the opposite case both measures will be negative and significant. Non-significant values imply that MVO is neither helpful nor harmful. The presence and extent of MVO were determined in patients with vs. without events during follow-up, and time-to-first event analyses were examined according to MVO tertiles. Categorical variables were compared using the v 2 test or a Fisher's exact test if the expected cell frequencies were <5. Continuous variables are displayed as median with the corresponding interquartile range (IQR) and were compared using the ttest or the Wilcoxon rank-sum test if the assumption of normality was violated. Time-to-event data are displayed as Kaplan-Meier estimates.
The relationship between MVO and infarct size was calculated by Spearman's rank-correlation coefficient. All P-values are two-sided, and P < 0.05 was considered statistically significant. All analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC, USA).
Results

Trials, patients, and microvascular obstruction
A total of 1688 patients with STEMI in whom CMR was performed within 7 days after primary PCI were enrolled in seven randomized trials between 2004 and 2011, comprising the study population. The design specifications of the included studies are shown in Table 1 , and the baseline features of the included patients are shown in Table 2 .
Clinical follow-up was prespecified through 6 months in four of the trials and through 1 year in three trials. The median duration from time of study entry to last clinical follow-up for all seven trials was 365 days (IQR 188-374).
The median time to CMR was 3 days (IQR 2-4). Microvascular obstruction was present in 56.9% (n = 960) of patients, and the median extent of MVO (expressed as the percent of left ventricular myocardial mass) was 0.47% (IQR 0.00-2.54). Baseline characteristics according to the presence of MVO are shown in Table 2 .
Relationship between microvascular obstruction and adverse events
The Kaplan-Meier estimated 1-year rates of all-cause mortality, HF hospitalization, and reinfarction after study entry were 2.4% (38 events), 2.8% (44 events), and 2.2% (34 events), respectively. In unadjusted analyses, a significant relationship was present between MVO and outcome measures excluding reinfarction ( Figure 2 ). When considered in tertiles of MVO, a graded response was present between MVO and all-cause mortality and HF hospitalization, but not reinfarction ( Figure 3) . By multivariable analysis, MVO was a strong independent predictor of all-cause mortality, HF hospitalization, and the composite occurrence of all-cause mortality or HF hospitalization, but not reinfarction ( Table 3) . Net reclassification improvement and IDI indicated incremental prognostic utility of MVO for the prediction of death or HF hospitalization when added to a standard multivariable model without MVO. As shown in Table 4 , the significance of the NRI for all-cause mortality, hospitalization for HF or the combination of death or HF hospitalization was largely attributable to a reduced predicted probability of an event in the non-event groups. Specifically, when MVO was added to the equation, the predicted probability of an event was lower for 78% of the non-events for all-cause mortality, for 75% of the non-events for hospitalization for HF, and for 76% of the non-events for all-cause mortality or hospitalization for HF. The relationship between MVO and all-cause mortality or HF hospitalization was consistent across multiple subgroups ( Figure 4) .
Patients with MVO had a larger infarct size compared with those without MVO [25.6% (IQR 17.4-36.5) vs. 10 .7% (IQR 4.1-19.1), P < 0.001]. The correlation between MVO and infarct size was moderate (r = 0.65, P < 0.001; Figure 5 ). Considering patients with (i) MVO < _ median and infarct size < _ median; (ii) MVO > median and infarct size < _ median; (iii) MVO < _ median and infarct size > median; and (iv) MVO > median and infarct size > median, a risk gradient across Relationship between microvascular obstruction and adverse events
the four groups was present for the composite 1-year rate of death or HF hospitalization (1.3% vs. 3 .5% vs. 5 .6% vs. 7 .1%, P < 0.001; Figure 6 Summarizing Figure) . In multivariable analyses adjusting for both MVO and infarct size, MVO remained significantly associated with all-cause mortality, but not with HF hospitalization, whereas infarct size was an independent predictor of both mortality and HF hospitalization ( Table 5) . Results were confirmed in analyses limited to patients with successful revascularization defined as final TIMI flow 2 or 3 (see Supplementary material online, Tables S1 and S2). The variance inflation factor for MVO vs. the entire covariate set was 1.82, which is not indicative of a high degree of multicollinearity. The square root of this value ( 1.35) indicates only a 35% increase in the standard error for the MVO regression coefficient.
Discussion
The present IPD pooled analysis from seven randomized trials of primary PCI in STEMI demonstrates a strong independent relationship between MVO measured within 7 days after reperfusion and the occurrence of all-cause death, hospitalization for HF, and the composite measure of all-cause death or HF hospitalization within 1 year. Assessment of MVO contributed to the classification of patient risk and improved discrimination of the risk of death or HF hospitalization during 1-year follow-up. Even after adjustment for infarct size, MVO remained independently predictive of all-cause mortality. Conversely, MVO was not an independent predictor of reinfarction after primary PCI in STEMI. location, baseline TIMI flow, and symptom-to-device time, variables which also strongly correlate with mortality after primary PCI.
26-29
Nonetheless, we observed a strong relationship between MVO and mortality, even after adjusting for these and other potential baseline confounding variables. In the fully adjusted model, every 1% absolute increase in MVO extent was independently associated with a 14% relative increase in 1-year all-cause mortality and an 8% increase in 1-year HF hospitalization. Moreover, anterior infarct location, baseline TIMI flow, and symptom-to-device time were not significant predictors of outcomes in these adjusted models, suggesting that their prognostic impact may be mediated through greater MVO. A strong graded response was present between MVO and the composite 1-year rate of all-cause mortality or HF hospitalization, with a threefold difference in the tertile of patients with absent MVO vs. the upper tertile of MVO (>1.55%).
The pathophysiologic mechanisms through which MVO adversely impacts prognosis are likely multifactorial. Microvascular obstruction limits the delivery and transit of endogenous promoters responsible for post-infarction remodelling, as well as macrophages required for phagocytosis of cellular debris needed for optimal infarct healing. 30 ............................................................................................................................................................................................................ [32] [33] [34] Animal models demonstrate increased myocardial stiffness and reduced elasticity in the infarcted regions in the presence of MVO, resulting in increased local wall stress with limited systolic shortening in adjacent segments. 35 Microvascular obstruction has also been associated with increased wall thinning and less improvement of wall thickening over several months following acute STEMI, independent of the extent of myonecrosis and the degree of infarct transmurality. 32 Conversely, the absence of MVO has been shown to be an independent predictor of left ventricular recovery as reflected in improved left ventricular ejection fraction over time. 33, 34 Finally, in the present study the presence and extent of MVO remained an independent predictor of mortality after adjusting for infarct size (although MVO was no longer an independent predictor of HF hospitalization). Further studies are thus warranted to elucidate the mechanisms through which MVO worsens survival independent of its direct effects on increasing infarct size. Infarct size was an independent predictor of both mortality and HF hospitalization. The present study demonstrates that MVO as assessed by CMR within several days after primary PCI provides prognostically relevant information in patients with STEMI. A reasonable hypothesis that may also be drawn from our results is that interventions which reduce MVO may thus improve prognosis. However, the present study can only demonstrate associations, and not prove causality. Thus, randomized trials are required to determine whether reducing MVO improves survival or freedom from HF. In this regard, interventions that reliably reduce MVO and improve prognosis after primary PCI have proven elusive.
Several additional limitations of this study should be acknowledged. First, the included trials varied with respect to inclusion and exclusion criteria. However, the strong correlation between MVO and all-cause mortality or HF hospitalization was consistent across all examined subgroups. Second, although all clinical endpoints were adjudicated by an independent committee in each trial, their definitions and methods of ascertainment and adjudication varied between studies. Moreover, adjudication of mortality type was not performed in all studies. The relationship between MVO and cardiac mortality may have been stronger than for all-cause mortality. Third, several variables related to either MVO or survival in past studies, such as Killip class and angiographic collaterals, were not uniformly available and were thus not included in the present study. Similarly, left ventricular function, volumes, and remodelling as well as intramyocardial haemorrhage were not assessed in all patients and thus their prognostic impact could not be reliably compared with MVO. Finally, the current results are not applicable to patients with contraindications for CMR. Consequently, the impact of MVO on outcome in patients with severe renal insufficiency and prior pacemaker or cardioverterdefibrillator implantation remains unclear. However, there is no pathophysiological basis to believe the results would differ in these patient groups. Despite these limitations, the present study is the largest and most robust examination of the relationship between MVO and prognosis after reperfusion therapy to date.
In conclusion, in the present pooled IPD analysis from seven randomized trials, MVO measured by CMR within 7 days after primary PCI was strongly associated with all-cause mortality and hospitalization for HF within 1 year. Microvascular obstruction therefore provides relevant prognostic information in patients with STEMI, and may be useful as an endpoint in future clinical trials. Infarct size measurement provides additional and complementary prognostic information to MVO assessment, and thus evaluating both parameters in the first few days after reperfusion therapy affords comprehensive characterization of the patient with recent STEMI. 
Supplementary material
Supplementary material is available at European Heart Journal online.
Funding
The present study was funded by the Cardiovascular Research Foundation, New York, NY, USA. The funding sources for the component trials of this analysis have been previously described. 
